Artificial intelligence (AI) is becoming increasingly important in our daily lives. AI can automate routine and time-consuming tasks, allowing us to focus on more important activities. In addition, AI algorithms can analyze vast amounts of data to personalize products, services and experiences. Moreover, AI is driving innovation in various industries, such as finance, retail and education. Here are seven artificial intelligence examples in everyday life.

Artificial intelligence (AI) is becoming increasingly important in our daily lives. AI can automate routine and time-consuming tasks, allowing us to focus on more important activities. In addition, AI algorithms can analyze vast amounts of data to personalize products, services and experiences. Moreover, AI is driving innovation in various industries, such as finance, retail and education. Here are seven artificial intelligence examples in everyday life.

Orchestration--of AI and of workflow--offers a new way to help imaging organizations improve radiologists' reading experience while significantly reducing the impact on IT IBM (NYSE: IBM) Watson Health is introducing a new AI orchestration offering to help imaging organizations experience the benefits of having AI applications work seamlessly together. IBM Watson Health will officially launch IBM Imaging AI Orchestrator at the Radiological Society of North America (RSNA) 2021 Annual Meeting in Chicago this week. In addition, IBM is announcing IBM Imaging Workflow Orchestrator with Watson, a new solution that modernizes the radiologist's reading experience while reducing the demands on IT and imaging system administrators. "We recognize that when it comes to applying AI in imaging, it's hard to go it alone," said David Gruen, MD, MBA, FACR, Chief Medical Officer, Imaging, Watson Health. "Because each AI application is developed in a unique way with a specific purpose, it can be challenging for organizations to review and assess each one, and then to deploy them in a way that's beneficial to radiologists and their patients. That's why, with the rapid proliferation of approved algorithms, staffing shortages, and complexity of disease, the IBM Imaging AI Orchestrator could not come at a better time."

Stratasys Ltd. a leader in polymer 3D printing solutions, announced a partnership with Ricoh USA, Inc. to provide point-of-care anatomic modeling services to healthcare facilities. RICOH 3D for Healthcare utilizes Stratasys 3D printing technology as part of its solution to give more medical providers and hospitals access to 3D printed, patient-specific anatomic models. RICOH 3D for Healthcare is an end-to-end workflow that simplifies the development, design, and production of anatomic models1 for healthcare providers. The solution increases medical facility access to 3D printed medical models to help clinicians see inside anatomy for greater visibility into patient needs and reduces barriers to entry that healthcare providers encounter when standing up a 3D printing facility. These include staffing issues, training requirements, HIPAA, quality and IT compliance, as well as budget constraints.

Some say that artificial intelligence (AI) will radically change healthcare in the future. But that prediction overlooks an important detail: AI is already significantly changing healthcare. IBM (NYSE:IBM) Watson Health general manager Deborah DiSanzo spoke at the annual J. P. Morgan Healthcare Conference on Wednesday. She provided an update on the progress that IBM Watson, the AI system famous for beating Jeopardy! DiSanzo highlighted four areas where AI is making a big difference today.

Better access to data-driven technology as procured by healthcare organisations can enhance healthcare and expand business endorsements. But, it is not simple for the company enterprise systems to utilise the many gigabytes of health and web data. But, not to worry, the drivers of NLP in healthcare are a feasible part of the remedy. The NLP illustrates the manners in which artificial intelligence policies gather and assess unstructured data from the language of humans to extract patterns, get the meaning and thus compose feedback. This is helping the healthcare industry to make the best use of unstructured data.

With IBM's recent exploration to sell off its health business unit IBM Watson Health, The Wall Street Journal highlighted several issues with AI in healthcare that can hinder tech companies' innovation efforts. Despite spending several billion dollars on acquisitions to scale Watson Health, IBM's health business currently isn't profitable and is looking to sell, according to the Journal. IBM declined to comment on the sale, but offered the following statement to the publication about its successes over the past decade. "This work began nearly 10 years ago, at the beginning of the AI revolution, and we explored groundbreaking space in helping physicians advance healthcare through AI," the company said. "IBM is continuing to evolve the Watson Health business, based on our decade of experience, to meet the needs of patients and physicians."

International Business Machines Corp. is exploring a potential sale of its IBM Watson Health business, according to people familiar with the matter, as the technology giant's new chief executive moves to streamline the company and become more competitive in cloud computing. IBM is studying alternatives for the unit that could include a sale to a private-equity firm or industry player or a merger with a blank-check company, the people said. The unit, which employs artificial intelligence to help hospitals, insurers and drugmakers manage their data, has roughly $1 billion in annual revenue and isn't currently profitable, the people said. Its brands include Merge Healthcare, which analyzes mammograms and MRIs; Phytel, which assists with patient communications; and Truven Health Analytics, which analyzes complex healthcare data. It isn't clear how much the business might fetch in a sale, and there may not be one. IBM, with a market value of $108 billion, has been left behind as cloud-computing rivals Microsoft Corp. and Amazon.com

The drug development lifecycle is long and fraught with heavy risk -- it takes a staggering 10 – 15 years on average, with ultimately only 12 percent of drugs in clinical trials gaining approval by the U.S. Food and Drug Administration (FDA) [1]. To put this in perspective, 22.7 percent of all global research and development spending in 2017 was in the healthcare industry, second only to 23.1 percent spent in the computing and electronics industry, yet the product lifecycle is longer, and costs are much higher [2]. For example, the original iPhone took two and a half years to develop from concept to launch, and an estimated $150 million spent in research and development [3]. In contrast, the average cost of new drug and biologics is $2.87 billion when factoring in the post-approval research and development costs, according to figures released in May 2016 by The Tufts Center for the Study of Drug development (CSDD) [4]. For pharmaceutical companies that have launched more than four drugs, the median cost is closer to a staggering $5.3 billion according to analysis by industry expert Matthew Herper of Forbes [5].

FirstWord MedTech's Digital Ten is a fortnightly round-up of the 10 most read and noteworthy headlines related to digital health, including industry deals, alliances, collaborations, innovations and R&D news. Insulet, the company behind the Omnipod tubeless wearable insulin delivery system, is partnering with Abbott to integrate the latter's Freestyle Libre continuous glucose monitoring (CGM) sensor with its new-generation Omnipod Horizon automated insulin delivery (AID) system onto a digital platform. The companies will make their respective technologies compatible so they can be paired and share CGM and insulin dosing data on a digital platform. Abbott has similar partnerships with Novo Nordisk and Sanofi, in which the CGM tech will be developed to share data with the drug companies' connected insulin pens. Abbott also counts Bigfoot Biomedical and Tandem Diabetes Care among its insulin delivery partners.